Physician

Cardiology

Dr. John H. Ip, MD

Doctor John H. Ip, MD works in the field of Cardiology. He went to medical school at University of Chicago Pritzker School of Medicine. University of Chicago Pritzker School of Medicine is ranked 10 in research and 19 in primary care medicine He received awards:"Meaningful Use Stage 1 Certification" and "Fellow (FACC)". John is a published MD. He published 36 publications, including: 'Cardiac arrhythmias in the elderly.' John accepts Medicare.

Publications

Surveillance of AF recurrence post-surgical AF ablation using implantable cardiac monitor.
Programming antitachycardia pacing for Primary prevention in patients with implantable cardioverter defibrillators: results from the PROVE trial.
Role of microvolt T-wave alternans in assessment of arrhythmia vulnerability among patients with Heart failure and systolic dysfunction: primary results from the T-wav...
Implantable cardioverter defibrillator therapy in patients with ischemic or non-ischemic Cardiomyopathy and nonsustained ventricular tachycardia.
Post Myocardial infarction stratification and the signal-averaged electrocardiogram.
Importance of experimental models for the development of clinical trials on thromboatherosclerosis.
Determinants of pace-terminable ventricular tachycardia: implications for implantable antitachycardia devices.
Myocardial preservation during ischemia and reperfusion.
Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation.
The role of platelets, thrombin and hyperplasia in restenosis after Coronary angioplasty.
Management of mobile right Atrial thrombi: a therapeutic dilemma.
The role of parasympathetic modulation of the reentrant arrhythmic substrate in the genesis of sustained ventricular tachycardia.
Identification of patients with high risk of arrhythmic mortality. Role of ambulatory monitoring, signal-averaged ECG, and Heart rate variability.
Tweaking the signal-averaged electrocardiogram in search of improved predictive accuracy.
Predictors of long-term survival in patients with malignant ventricular Arrhythmias.
Subpectoral implantation of cardioverter-defibrillator combined with a nonepicardial lead system: preliminary experience with a novel approach.
Determinants of induction of ventricular tachycardia in nonsustained ventricular tachycardia after Myocardial infarction and the usefulness of the signal-averaged elec...
Total pectoral implantation: a new technique for implantation of transvenous defibrillator lead systems and implantable cardioverter defibrillator.
A useful marker during ablation.
A preventable pacemaker problem.
Lower loop reentry as a mechanism of clockwise right Atrial flutter.
Oral d,l sotalol reduces the incidence of postoperative atrial fibrillation in Coronary artery bypass surgery patients: a randomized, double-blind, placebo-controlled ...
Cardiac Arrhythmias in the elderly.
Subpectoral implantation of ICD generators: long-term follow-up.
Atrial overdrive pacing and incidence of Heart failure-related adverse events in permanently paced patients.
Circadian variation in sudden cardiac death: effects of age, sex, and initial cardiac rhythm.
A new pacemaker algorithm for the treatment of Atrial fibrillation: results of the Atrial Dynamic Overdrive Pacing Trial (ADOPT).
Impact of Atrial prevention pacing on Atrial fibrillation burden: primary results of the Study of Atrial Fibrillation Reduction (SAFARI) trial.
Multicenter randomized study of anticoagulation guided by remote rhythm monitoring in patients with implantable cardioverter-defibrillator and CRT-D devices: Rationale...
The impact of atrial prevention and termination therapies on atrial tachyarrhythmia burden in patients receiving a dual-chamber defibrillator for ventricular Arrhythmias.
Statin use was associated with reduced mortality in both ischemic and nonischemic Cardiomyopathy and in patients with implantable defibrillators: mortality data and me...
Evolution of curative therapies for Atrial fibrillation review.
Amiodarone or an implantable cardioverter-defibrillator for congestive Heart failure.
A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset Atrial fibrillation.
Vernakalant hydrochloride for rapid conversion of Atrial fibrillation: a phase 3, randomized, placebo-controlled trial.

Schools

U Of Chgo Div Of Bio Sci Pritzker Sch Of Med
New York University School Of Med
Mt Sinai Hospital

Procedures Preformed

Ablation for Treatment of Cardiac Arrhythmias
Automatic Implantable Cardioverter Defibrillator (ICD) Implantation
Cardiac Catheterization (incl. Coronary Angiography)
Cardiac Imaging
View All

Conditions Treated

Aneurysm and Dissection of Heart
Angina and Acute Coronary Syndrome
Aortic Aneurysm
Aortic Ectasia
View All

Doctors Specialties

Cardiology
Clinical Cardiac Electrophysiology

Accepted Insurances

Awards

Meaningful Use Stage 1 Certification
Fellow (FACC)

Education

Mount Sinai School of Medicine
NYU School of Medicine
University of Chicago Pritzker School of Medicine

Hospital

McLaren Greater Lansing

Drug Facts

NPI NUMBER		1326049032
NPPES Provider LastName		IP
NPPES Provider FirstName		JOHN
NPPES Provider ZIPCode		489102898
NPPES Provider State		MI
Specialty Description		Cardiology
Total Claim Count		1356.0
Distinct Opioid Count		1.0
Opioid Claim Count		20.0
Percent Opioid Claims		1.47

Helpful Reviews

Give Anonymous Review

Medicare Facts

National Provider Identifier [NPI]	1326049032
Last Name Of The Provider	IP
First Name Of The Provider	JOHN
View All

Similar Doctors

	Dr. Ashok J. Shah, MD
	Dr. Mark Veenendaal, MD This Doctor is OpenDoctor Recommended.
	Dr. Ranjan K. Thakur, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Juan O. Hernandez, MD This Doctor is OpenDoctor Recommended.
	Dr. Christopher M. D'Haem, DO
	Dr. Milind M. Karve, MD This Doctor is OpenDoctor Recommended.
	Dr. Thomas M. Brown, MD
	Dr. David K. Rhine, MD This Doctor is OpenDoctor Recommended.